Drug Trial Radar · NCT07889505
A Phase 2 Two-Part Study of Oral PS1 in Healthy Volunteers and Adults With Newly Diagnosed Type 1 Diabetes
Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
Nov 21, 2026
Primary completion
Aug 15, 2028
Study completion Oct 31, 2028
Sponsor
- Lead sponsor
- Pharmasaga Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study consists of 2 sub-studies, including Part A and Part B. Part A is intended to further characterize the pharmacokinetic (PK) profile of PS1 based on existing single ascending dose (SAD) and multiple ascending dose (MAD) data, while Part B is designed as an exploratory study to evaluate the potential clinical effects of PS1 in adults with newly diagnosed type 1 diabetes mellitus (T1DM). PS1 is a potential blood glucose-lowering medication being developed by Pharmasaga Co., Ltd. for the treatment of T1DM.
Conditions
- Type 1 Diabetes Mellitus
Interventions
PS1Drug
PS1 will be provided as a 120 mg tablet with 25 mg active pharmaceutical ingredient.
PlaceboDrug
Placebo will be provided as a 120 mg tablet.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part B: Change from Baseline in 4-Hour Mixed-Meal Tolerance Test (MMTT)-Stimulated C-Peptide Area Under the Curve (AUC)Time frame: Part B: Approximately 4 months.
- Part A: Pharmacokinetics (PK) of PS1Time frame: Day 1-2: predose, and 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours after dosing & Day 8.
- Part A: Pharmacokinetics (PK) of PS1Time frame: Day 1-2: predose, and 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours after dosing & Day 8.
- Part A: Pharmacokinetics (PK) of PS1Time frame: Day 1-2: predose, and 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours after dosing & Day 8.
- Part A: Pharmacokinetics (PK) of PS1Time frame: Day 1-2: predose, and 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours after dosing & Day 8.
- Part A: Pharmacokinetics (PK) of PS1Time frame: Day 1-2: predose, and 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours after dosing & Day 8.
- Part A: Pharmacokinetics (PK) of PS1Time frame: Day 1-2: predose, and 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours after dosing & Day 8.
- Part A: Pharmacokinetics (PK) of PS1Time frame: Day 1-2: predose, and 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours after dosing & Day 8.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.